Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced that the first phase III data on their investigational compound brexpiprazole will be presented in an upcoming poster session at the 22(nd) European Psychiatry Association Congress (EPA) on March 2, 2014. Data will be presented from a completed phase III, randomized, placebo-controlled study investigating the effect of brexpiprazole as adjunctive therapy to antidepressant therapy in patients with major depressive disorder (MDD). Overall, brexpiprazole demonstrated efficacy and was well tolerated as an adjunctive treatment for MDD patients with an inadequate response to antidepressant treatment.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7,319 JPY | 0.00% |
|
+1.53% | +38.19% |
07-10 | Jefferies Adjusts Otsuka Holdings' Price Target to 8,100 Yen From 7,800 Yen, Keeps at Buy | MT |
07-09 | Indivior shares dive on profit warning, dropping of schizophrenia drug (July 9) | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.19% | 24.34B | |
+25.40% | 45.35B | |
+27.09% | 16.51B | |
+21.19% | 14.6B | |
+71.91% | 14.27B | |
-0.05% | 6.79B | |
-10.93% | 6.57B | |
+13.07% | 5.76B | |
-8.87% | 5.73B | |
+35.45% | 5.01B |
- Stock Market
- Equities
- 4578 Stock
- News Otsuka Holdings Co., Ltd.
- Otsuka and Lundbeck to Present New Data on Brexpiprazole in Major Depressive Disorder at European Psychiatry Association 2014 Congress